A comprehensive review of vaccination in patients with inflammatory bowel diseases:  An Indian perspective

Shah, Bhavik; Goenka, Mahesh Kumar

doi:10.1007/s12664-020-01069-0

Cited by 3 publications

(5 citation statements)

References 77 publications

(87 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast, patients with IBD did not suffer from an increased frequency of IBD flares after SARS-CoV-2 vaccination. Recent studies also proved the safety of other vaccines, such as the influenza vaccine, in patients with IBD [13,14]. A recent umbrella review of meta-analyses showed that vaccinations are not associated with an increased risk of IBD [15].…”

Section: Discussionmentioning

confidence: 99%

SARS-CoV-2 vaccination does not induce relapses of patients with inflammatory bowel disease

et al. 2022

View full text Add to dashboard Cite

Background Vaccination against SARS-CoV-2 is a promising strategy to protect immunocompromised IBD patients from a severe course of COVID-19. As these patients were excluded from initial clinical vaccination trials, patients frequently express concerns regarding the safety of these vaccines, especially whether vaccination might trigger IBD flares (“hit-and-run-hypothesis”). Methods In order to assess the risk of an IBD flare after vaccination against SARS-CoV-2, an anonymous survey was performed at five German IBD centers and one patient organization (Deutsche Morbus Crohn/Colitis ulcerosa Vereinigung (DCCV) e.V.) in August and October 2021. Results The questionnaire was answered by 914 patients, 781 of whom reported a previous vaccination against SARS-CoV-2 (85.4%). Vaccination against SARS-CoV-2 was not associated with an increased risk of IBD flares (p=0.319) or unscheduled visits to the IBD physician (p=0.848). Furthermore, typical symptoms of an IBD flare including abdominal pain, increases in stool frequency, or rectal bleeding were not influenced by the vaccination. Conclusion Vaccination against SARS-CoV-2 is safe in IBD patients. These results may help to reduce fears regarding the vaccination in IBD patients. Our results can help to reduce fears in IBD patients regarding the SARS-CoV-2 vaccine. A close communication between patients and physicians before and after the vaccination may be beneficial.

show abstract

Section: Discussionmentioning

confidence: 99%

SARS-CoV-2 vaccination does not induce relapses of patients with inflammatory bowel disease

et al. 2022

View full text Add to dashboard Cite

show abstract

“…The vaccination of individuals with IBD varies according to the recommendations of each country, as well as by the clinical judgment of the patient's healthcare provider[ 124 ]. It is recommended that these patients be vaccinated before starting immunosuppressive therapy, and if they have already started, vaccines with live viruses should be avoided[ 125 , 126 ]. Some authors recommend mandatory immunizations for these patients, including vaccines against influenza, chickenpox, hepatitis B, and triple viral.…”

Section: Clinical Management Of the Crohn’s Disease Today: How It Does?mentioning

confidence: 99%

“…If the test results are negative or show very low antibody levels, these patients should restart the vaccination schedule with three doses. Additionally, individuals over 50 years old should be immunized against the herpes zoster virus, and persons aged 9 to 45 years should be vaccinated for HPV, preferably covering the four main strains (6, 11, 16, and 18)[ 126 - 128 ]. The pneumococcal vaccine should be administered to all patients, following the recommendations of national immunization programs for chronic diseases[ 125 ].…”

Section: Clinical Management Of the Crohn’s Disease Today: How It Does?mentioning

confidence: 99%

“…The pneumococcal vaccine should be administered to all patients, following the recommendations of national immunization programs for chronic diseases[ 125 ]. Influenza immunization should be done annually[ 126 ]. Furthermore, in the current context, coronavirus disease 2019 (COVID-19) vaccination is essential.…”

Section: Clinical Management Of the Crohn’s Disease Today: How It Does?mentioning

confidence: 99%

See 1 more Smart Citation

Crohn's disease and clinical management today: How it does?

da Silva Júnior,

Apolonio,

de Souza Nascimento

et al. 2023

World J Methodol

View full text Add to dashboard Cite

Crohn’s Disease (CD) is an Inflammatory Bowel Disease and is characterized by an immune-mediated nature. Its etiology results from the interaction between genetic, enviromental and microbial factors. Regarding pathophysiology, it involves high levels of interleukin (IL)-12, IL-17, and Th1 profile, along with loss of tolerance mechanisms, an increase in pro-inflammatory interleukins, beyond the possibility to affect any part of the gastrointestinal tract. Its symptoms include abdominal pain, chronic diarrhea, weight loss, anorexia, and fatigue, as well as blood in the stool or rectum. Additionally, conditions comprising musculoskeletal, cutaneous, ocular, hepatic, and hematological alterations may be associated with this scenario and extra-intestinal presentation, such as erythema nodosum, anterior uveitis, osteoporosis, and arthritis can also occur. Today, clinical history, exams as fecal calprotectin, ileocolonocopy, and capsule endoscopy can be performed in the diagnosis investigation, along with treatments to induce and maintain remission. In this sense, anti-inflammatory drugs, such as corticosteroids, immunomodulators, and biological agents, as well as surgery and non-pharmacological interventions plays a role in its therapy. The aim of this review is to bring more current evidence to clinical management of CD, as well as to briefly discuss aspects of its pathophysiology, surveillance, and associated disorders.

show abstract

“…It is well known that immunosuppression impairs the ability of the immune system to effectively respond to vaccination. Although recent reviews have examined the response to vaccination in patients who are immunosuppressed due to a particular disease state, 1 , 2 very few studies have examined the effect of immunosuppressive drug therapy on the response to inactivated vaccines. Though inactivated vaccines are generally considered safe in immunocompromised patients due to their inability to cause infection, questions regarding their efficacy, and whether all immunosuppressive drugs impact vaccine efficacy equally, remain.…”

Section: Introductionmentioning

confidence: 99%

Efficacy of inactivated vaccines in patients treated with immunosuppressive drug therapy

Bemben

Berg

2022

Pharmacotherapy

View full text Add to dashboard Cite

Inactivated vaccines are generally considered safe in immunocompromised patients but the ability of immunocompromised patients to generate an effective immune response to vaccines is uncertain. Although recent reviews have focused on the effects of vaccines in patients who are immunocompromised due to various disease states (primary immunodeficiency), the effects of immunosuppressive drug therapy (secondary immunodeficiency) has received relatively less attention. This review evaluates evidence regarding the efficacy of inactivated vaccines against influenza, COVID-19, and other diseases in patients treated with immunosuppressive oncologic agents, immunosuppressants used for transplant recipients, and immunosuppressants used for autoimmune disorders. Although evidence is mixed for many immunosuppressive agents and vaccines, most studies have found an attenuated immune response to inactivated vaccines, with the majority of data indicate anti-B-cell antibodies have a more severe and prolonged negative effect on vaccine efficacy. K E Y W O R D S antirheumatic agents, immunosuppressive agents, inactivated vaccine, vaccine | 335 BEMBEN aNd BERG over 10 kg], as defined by the Advisory Committee on Immunization Practices [ACIP]), were considered to be immunosuppressive agents. 4 How to cite this article: Bemben NM, Berg ML. Efficacy of inactivated vaccines in patients treated with immunosuppressive drug therapy. Pharmacotherapy.

show abstract

A comprehensive review of vaccination in patients with inflammatory bowel diseases: An Indian perspective

Cited by 3 publications

References 77 publications

SARS-CoV-2 vaccination does not induce relapses of patients with inflammatory bowel disease

SARS-CoV-2 vaccination does not induce relapses of patients with inflammatory bowel disease

Crohn's disease and clinical management today: How it does?

Efficacy of inactivated vaccines in patients treated with immunosuppressive drug therapy

Contact Info

Product

Resources

About